Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

CR Bard buys majority interest in X-Trode:

This article was originally published in Clinica

Executive Summary

CR Bard has bought a majority stake in Italian coronary stent manufacturer X-Trode. Chairman and CEO of Bard, William Longfield, says the purchase will provide Bard with a stainless steel coronary stent superior to those already on the market. Terms of the deal were not disclosed.

You may also be interested in...



Novartis Targets Ten Indications For Cosentyx

The Swiss giant is hoping to get seven more approvals for its blockbuster immunology drug over the next 10 years.

Zydus Cadila Strides Ahead With NASH Filing In India

Cadila has filed for approval of saroglitazar for NASH in India. The drug, which could emerge as the first medicine for the indication if approved, is already being used by a million Indian patients for diabetic dyslipidemia and hypertriglyceridemia.

 

Interview: Double Delight For ImmuPharma's Dimitriou

It has been a long and sometimes tortuous development path for Lupuzor but ImmuPharma's chief executive tells Scrip the company's faith in the lupus drug is bearing fruit.

Topics

UsernamePublicRestriction

Register

MT087355

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel